Arvinas, Inc. (NASDAQ:ARVN) Stock Position Increased by New Leaf Venture Partners L.L.C.

New Leaf Venture Partners L.L.C. grew its holdings in Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 10.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,585,721 shares of the company's stock after purchasing an additional 151,000 shares during the period. Arvinas makes up 40.6% of New Leaf Venture Partners L.L.C.'s investment portfolio, making the stock its largest position. New Leaf Venture Partners L.L.C. owned 2.31% of Arvinas worth $30,398,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of ARVN. KBC Group NV lifted its stake in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Arvinas in the 4th quarter valued at $171,000. Teacher Retirement System of Texas lifted its stake in Arvinas by 19.0% during the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock worth $274,000 after acquiring an additional 2,280 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Arvinas by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after acquiring an additional 1,367 shares during the period. Finally, LPL Financial LLC boosted its holdings in Arvinas by 12.5% during the 4th quarter. LPL Financial LLC now owns 18,669 shares of the company's stock valued at $358,000 after acquiring an additional 2,077 shares during the period. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Stock Up 12.4 %

ARVN traded up $0.95 on Friday, hitting $8.60. 3,186,900 shares of the company traded hands, compared to its average volume of 1,120,109. The stock has a market capitalization of $591.44 million, a PE ratio of -3.10 and a beta of 2.30. The company has a 50 day moving average of $11.49 and a 200-day moving average of $18.64. Arvinas, Inc. has a 12-month low of $5.94 and a 12-month high of $37.38.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the prior year, the company posted ($2.53) earnings per share. On average, research analysts anticipate that Arvinas, Inc. will post -3.81 EPS for the current year.

Analysts Set New Price Targets

ARVN has been the topic of several research reports. Truist Financial reduced their price target on shares of Arvinas from $65.00 to $21.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Barclays decreased their price target on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. The Goldman Sachs Group cut their price objective on Arvinas from $15.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday. HC Wainwright restated a "buy" rating and set a $81.00 target price on shares of Arvinas in a research note on Monday, April 7th. Finally, Citigroup decreased their price target on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday, March 7th. Five analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $34.33.

Insider Transactions at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the sale, the chief executive officer now directly owns 1,157,480 shares in the company, valued at approximately $19,353,065.60. This trade represents a 2.64 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Noah Berkowitz sold 8,658 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.59, for a total value of $74,372.22. Following the sale, the insider now directly owns 110,023 shares in the company, valued at $945,097.57. This trade represents a 7.30 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 50,230 shares of company stock valued at $769,402. Corporate insiders own 5.23% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.